Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption
Sponsor: Ciusss de L'Est de l'Île de Montréal
Summary
Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.
Official title: The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption: a Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2024-11
Completion Date
2025-11
Last Updated
2024-11-12
Healthy Volunteers
Yes
Conditions
Interventions
Dexmedetomidine
Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.
Placebo
Saline will be used instead of dexmedetomidine
Locations (1)
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada